PMCB PharmaCyte Biotech, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Eyl 14, 2026
$0,40
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$0,3352 haftanın en düşüğü
$1,5152 haftanın en yükseği
Piyasa Değeri (MRQ)
$4M
P/E (TTM)
-0.2
Hisse Başına Kâr (TTM)
$-2.08
Gelir (TTM)
$0
rozetleriniz
52 Haftlık Aralık
$0–$2
Analist Derecelendirmesi
HOLD
Fiyat Hedefi
·
P/E
-0.2
ROE
-45.4%
Net Kâr Marjı
·
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
PMCB Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$0.40
Piyasa Değeri (MRQ)
$4M
P/E (TTM)
-0.2
Hisse Başına Kâr (TTM)
$-2.08
Gelir (TTM)
$0
ROE (TTM)
-45.4%
52 Haftlık Aralık
$0–$2
PMCB Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 12 Temmuz 2021 | 1-for-1550 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$02017-04-30 → 2026-04-30
Hisse Başına Kâr$-2.772021-04-30 → 2026-04-30
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | PMCB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -0.25Y ort. ≈-4.6 | ≈-4.6 | · | · | |
| F/D (MRQ) | 0.25Y ort. ≈0.3 | ≈0.3 | 0.4 | Düşük değerli | |
| Price / Cash Flow (Fiyat / Nakit Akışı) | -0.85Y ort. ≈-5.2 | ≈-5.2 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 0.15Y ort. ≈0.4 | ≈0.4 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | PMCB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| ROA (TTM) | -39.5%5Y ort. ≈0.35% | ≈0.35% | -102.1% | En üst düzey | |
| ROE (TTM) | -45.4%5Y ort. ≈0.11% | ≈0.11% | -421.6% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | PMCB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 40.35Y ort. ≈59.5 | ≈59.5 | 4.2 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 22.85Y ort. ≈54.4 | ≈54.4 | 1.2 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | PMCB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Net Income YoY (Net Gelir Yıllık Bazda) | 9085.0% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | PMCB | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$0.00 | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 31 Mart 2027 | Eyl 14, 2026 | $-0.54 | — | — |
| 31 Mart 2026 | $-0.09 | — | — | |
| 30 Eylül 2025 | $-0.10 | — | — | |
| 30 Haziran 2025 | $-0.29 | — | — | |
| 31 Mart 2025 | $0.14 | — | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| R&D Expense | $391.3K | $438.4K | $407.4K | $468.5K | $690.9K | $916.2K | $301.2K | $460.1K | $2M | $1M | $1M | $3M | |
| SG&A Expense | $5M | $4M | $6M | $1M | $1M | $418.1K | $1M | $1M | $2M | $744.8K | $2M | $2M | |
| Operating Expenses | $7M | $4M | $9M | $6M | $4M | $4M | $4M | $4M | $7M | $4M | $6M | $13M | |
| Operating Income | $-7M | $-4M | $-9M | $-6M | $-4M | $-4M | $-4M | $-4M | $-7M | $-4M | $-6M | $-13M | |
| Interest Expense | · | · | · | $0 | $509 | $3.0K | $453 | $0 | $0 | $1.5K | $1.2K | $4.9K | |
| Other Non-op | $-980 | $-965 | $191.1K | $202.0K | $-4.3K | $71.7K | $-493 | $33.4K | $152.6K | $-1.5K | $9.3K | $3M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-19M | $31M | $333.8K | $-4M | $-4M | $-4M | $-4M | $-4M | $-7M | $-4M | $-6M | $-10M | |
| EPS (Basic) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | · | · | · | · | · | · | |
| EPS (Diluted) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | · | · | · | · | · | · | |
| Shares (Basic) | 8,378,291 | 7,329,596 | 9,581,059 | 19,489,204 | 15,521,654 | 1,448,285 | 903,812 | 1,100,104,338 | 968,641,686 | 845,308,413 | 752,403,049 | 704,327,656 | |
| Shares (Diluted) | 8,378,291 | 7,329,596 | 9,581,059 | 19,489,204 | 15,521,654 | 1,448,285 | 903,812 | 1,100,104,338 | 968,641,686 | 845,308,413 | 752,403,049 | 704,327,656 | |
| EBITDA | $-7M | $-4M | $-9M | $-6M | $-4M | $-4M | $-4M | $-4M | $-7M | $-4M | $-6M | · |
Bilanço
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $15M | $50M | $68M | $85M | $2M | $894.9K | $515.3K | $1M | $3M | $2M | $3M | |
| Short-term Investments | $254.0K | $366.3K | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $96.9K | $223.8K | $259.8K | $107.7K | $94.2K | $73.1K | $142.8K | $138.2K | $224.1K | $74.3K | $110.0K | $1M | |
| Current Assets | $37M | $22M | $50M | $68M | $85M | $2M | $1M | $653.4K | $1M | $4M | $2M | $4M | |
| Intangibles | $0 | $2M | $2M | $4M | $4M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $7.7K | $7.7K | · | · | · | $7.4K | $7.4K | $7.4K | $7.4K | $7.4K | $7.9K | $7.9K | |
| Total Assets | $47M | $55M | $60M | $73M | $91M | $7M | $6M | $6M | $6M | $9M | $7M | $9M | |
| Accounts Payable | $271.1K | $399.2K | $389.4K | $128.3K | $205.4K | $172.3K | $185.8K | $121.9K | $352.6K | $365.6K | $336.0K | $496.7K | |
| Accrued Liabilities | $522.8K | $3M | $735.2K | $458.3K | $499.0K | $552.5K | $816.6K | $621.0K | $291.5K | $214.6K | $151.6K | $23.7K | |
| Current Liabilities | $826.4K | $3M | $7M | $586.6K | $704.4K | $724.8K | $1M | $742.9K | $644.2K | $580.2K | $637.6K | $2M | |
| Total Liabilities | $12M | $3M | $20M | $586.6K | $704.4K | $724.8K | $1M | $742.9K | $644.2K | $580.2K | $637.6K | $2M | |
| Common Stock | $2.6K | $2.2K | $2.2K | $2.2K | $2.1K | $159 | $109 | $118.6K | $101.3K | $90.5K | $78.1K | $73.3K | |
| Paid-in Capital | $183M | $181M | $185M | $202M | $202M | $114M | $109M | $105M | $102M | $97M | $91M | $86M | |
| Retained Earnings | $-104M | $-85M | $-116M | $-116M | $-112M | $-107M | $-104M | $-100M | $-96M | $-89M | $-85M | $-79M | |
| Treasury Stock | $45M | $45M | $42M | $14M | $0 | · | · | · | · | · | · | · | |
| AOCI | $-20.8K | $-23.9K | $-23.5K | $-23.0K | $-15.8K | $-20.4K | $-21.7K | $-13.8K | $-4.7K | $1.7K | $806 | $1.5K | |
| Stockholders' Equity | $33M | $52M | $28M | $73M | $90M | $7M | $5M | $5M | $6M | $8M | $7M | $8M | |
| Liabilities + Equity | $47M | $55M | $60M | $73M | $91M | $7M | $6M | $6M | $6M | $9M | $7M | $9M | |
| Shares Outstanding | 10,735,649 | 6,795,779 | 8,037,624 | 16,793,980 | 20,721,047 | 1,590,084 | 1,092,425 | 1,186,004,505 | 1,013,260,644 | 905,349,047 | 781,233,338 | 732,760,536 |
Nakit Akışı
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $892.5K | $0 | $674.7K | $7.3K | $33.1K | $194.3K | $368.6K | $293.3K | $580.4K | $420.5K | $405.1K | $735.2K | |
| Operating Cash Flow | $-5M | $-3M | $-2M | $-4M | $-4M | $-3M | $-2M | $-3M | $-5M | $-3M | $-4M | $-5M | |
| Investing Cash Flow | $2M | $-7M | $-5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | · | |
| Stock Issued | · | · | · | $0 | $87M | $5M | $3M | $2M | $3M | $5M | $4M | $4M | |
| Stock Repurchased | $401.6K | $3M | $28M | $14M | $0 | · | · | · | · | · | · | · | |
| Net Stock Activity | $-401.6K | $-3M | $-28M | $-14M | $87M | $5M | $3M | $2M | $3M | $5M | $4M | · | |
| Financing Cash Flow | $7M | $-25M | $-11M | $-14M | $87M | $5M | $3M | $2M | $3M | $5M | · | · | |
| Net Change in Cash | $3M | $-35M | $-18M | $-17M | $83M | $1M | $379.6K | · | · | · | · | · | |
| Taxes Paid | $0 | $0 | $1.6K | $0 | $1.6K | $800 | $800 | $800 | $800 | $800 | · | · |
Kârlılık
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -38.1% | 53.3% | 0.50% | -5.3% | -8.6% | -52.3% | -64.0% | -66.7% | -90.6% | -56.1% | -73.7% | · | |
| ROE | -56.7% | 66.5% | 1.1% | -5.8% | -4.7% | -49.7% | -81.3% | -78.2% | -117.7% | -60.8% | -84.8% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 45.3 | 7.7 | 6.8 | 116.2 | 121.4 | 3.1 | 1.0 | 0.9 | 2.0 | 6.1 | 3.2 | · | |
| Quick Ratio | 22.8 | 5.3 | 6.8 | 116.0 | 121.2 | 3.0 | 0.9 | 0.7 | 1.6 | 6.0 | 3.0 | · | |
| Interest Coverage | · | · | · | · | -8628.7 | -1189.4 | -8446.8 | · | · | -2886.4 | -5099.2 | · |
Verimlilik
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
Hisse Başına
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.10 | $7.64 | $3.44 | $4.33 | $56.55 | $4.20 | $0.00 | $0.00 | $0.01 | $0.01 | $0.01 | · | |
| Revenue / Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | |
| Cash Flow / Share | $-0.61 | $-0.41 | $-0.22 | $-0.19 | $-0.27 | $-2.30 | $-0.00 | $-0.00 | $-0.01 | $-0.00 | $-0.01 | · | |
| Cash / Share | $1.73 | $2.23 | $6.24 | $4.05 | $53.71 | $1.38 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | |
| EPS (TTM) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | · | · | · | · | · | · |
Büyüme Oranları
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income YoY | · | 9085.0% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income TTM | $-19M | $31M | $333.8K | $-4M | $-4M | $-4M | $-4M | $-4M | $-7M | $-4M | $-6M | $-10M | |
| Market Cap | $8M | $8M | $17M | $49M | $4M | $44M | $62.23B | $75.37B | $84.81B | $109.32B | $82.95B | · | |
| P/E | -0.3 | 0.4 | -1.2 | -13.3 | -8.6 | -11.2 | · | · | · | · | · | · | |
| P/B | 0.2 | 0.2 | 0.6 | 0.7 | 0.0 | 6.5 | 12227.9 | 14955.8 | 14701.8 | 13517.1 | 12716.8 | · | |
| P / Tangible Book | 0.2 | 0.2 | 0.7 | 0.7 | 0.0 | 6.5 | 12227.9 | · | · | · | · | · | |
| P / Cash Flow | -1.5 | -2.8 | -7.9 | -12.9 | -0.9 | -13.1 | -26611.4 | -26189.3 | -16696.9 | -32734.7 | -19084.1 | · | |
| Earnings Yield | -383.7% | 257.3% | -84.9% | -7.5% | -11.6% | -8.9% | · | · | · | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| R&D Expense | $60.0K | $61.9K | $93.1K | $141.1K | $95.2K | $126.7K | $118.2K | $97.5K | $96.0K | $94.2K | $126.7K | $82.0K | $104.5K | $85.9K | $45.4K | $178.0K | |
| SG&A Expense | $946.7K | $899.9K | $2M | $1M | $753.1K | $915.9K | $842.1K | $1M | $1M | $4M | $251.9K | $272.5K | $1M | $328.1K | $356.9K | $183.0K | |
| Operating Expenses | $1M | $3M | $2M | $1M | $848.3K | $1M | $960.3K | $1M | $1M | $3M | $2M | $1M | $2M | $903.3K | $2M | $2M | |
| Operating Income | $-1M | $-3M | $-2M | $-1M | $-848.3K | $-1M | $-960.3K | $-1M | $-1M | $-3M | $-2M | $-1M | $-2M | $-903.3K | $-2M | $-2M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Other Non-op | $-97 | $-132 | $-632 | $-95 | $-121 | $687 | $-400 | $-1.1K | $-190 | $194.0K | $-253 | $-765 | $-1.8K | $54.0K | $153.0K | $-1.1K | |
| Income Tax | $0 | · | · | · | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income | $-5M | $-4M | $746.9K | $-7M | $-8M | $12M | $-3M | $-1M | $23M | $1M | $-619.5K | $3M | $-3M | $-126.3K | $-764.1K | $-2M | |
| EPS (Basic) | $-0.54 | $-0.13 | $-0.17 | $-1.24 | $-1.23 | $2.12 | $-0.44 | $-0.39 | $1.90 | $-0.35 | $-0.65 | $-0.26 | $-0.54 | $-0.02 | $-0.04 | $-0.09 | |
| EPS (Diluted) | $-0.54 | $-0.13 | $-0.17 | $-1.24 | $-1.23 | $2.12 | $-0.44 | $-0.39 | $1.90 | $-0.35 | $-0.65 | $-0.26 | $-0.54 | $-0.02 | $-0.04 | $-0.09 | |
| Shares (Basic) | 10,735,649 | · | 9,262,829 | 6,795,779 | 6,795,779 | · | 6,960,014 | 7,637,034 | 7,866,387 | · | 8,606,957 | 8,765,134 | 12,601,891 | · | 18,995,442 | 20,585,451 | |
| Shares (Diluted) | 10,735,649 | · | 9,262,829 | 6,795,779 | 6,795,779 | · | 6,960,014 | 7,637,034 | 7,866,387 | · | 8,606,957 | 8,765,134 | 12,601,891 | · | 18,995,442 | 20,585,451 | |
| EBITDA | $-1M | · | $-2M | $-1M | $-848.3K | · | $-960.3K | $-1M | $-1M | · | $-2M | $-1M | $-2M | · | $-2M | $-2M |
Bilanço
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $19M | $20M | $15M | $13M | $15M | $16M | $21M | $33M | $50M | $61M | $73M | $75M | $68M | $73M | $77M | |
| Short-term Investments | $99.5K | $254.0K | $372.3K | $201.2K | $261.9K | $366.3K | $372.6K | · | · | $0 | · | · | · | · | · | · | |
| Prepaid Expense | $32.0K | $96.9K | $158.7K | $503.1K | $238.2K | $223.8K | $207.4K | $493.2K | $240.2K | $259.8K | $297.8K | $323.2K | $88.7K | $107.7K | $181.0K | $256.8K | |
| Current Assets | $31M | $37M | $21M | $23M | $19M | $22M | $17M | $21M | $33M | $50M | $62M | $74M | $75M | $68M | $73M | $77M | |
| Intangibles | · | $0 | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $4M | $4M | · | · | |
| Other Non-current Assets | $7.7K | $7.7K | · | · | · | $7.7K | · | · | · | · | · | · | · | · | · | · | |
| Total Assets | $37M | $47M | $56M | $56M | $45M | $55M | $44M | $55M | $70M | $60M | $71M | $79M | $80M | $73M | $78M | $82M | |
| Accounts Payable | $390.5K | $271.1K | $1M | $1M | $465.2K | $399.2K | $484.9K | $348.6K | $554.0K | $389.4K | $484.2K | $126.2K | $718.1K | $128.3K | $445.9K | $861.3K | |
| Accrued Liabilities | $345.7K | $522.8K | $445.7K | $520.7K | $595.7K | $3M | $709.4K | $707.2K | $684.1K | $735.2K | $774.4K | $1M | $480.0K | $458.3K | $381.9K | $449.9K | |
| Current Liabilities | $768.7K | $826.4K | $2M | $2M | $1M | $3M | $1M | $5M | $7M | $7M | $8M | $5M | $2M | $586.6K | $827.8K | $1M | |
| Total Liabilities | $7M | $12M | $16M | $19M | $2M | $3M | $4M | $12M | $17M | $20M | $22M | $21M | $20M | $586.6K | $827.8K | $1M | |
| Common Stock | $2.6K | $2.6K | $2.6K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | $2.2K | |
| Paid-in Capital | $182M | $183M | $183M | $181M | $182M | $181M | $181M | $181M | $183M | $185M | $189M | $194M | $202M | $202M | $202M | $202M | |
| Retained Earnings | $-109M | $-104M | $-100M | $-101M | $-93M | $-85M | $-97M | $-94M | $-92M | $-116M | $-117M | $-116M | $-119M | $-116M | $-116M | $-115M | |
| Treasury Stock | $45M | $45M | $45M | $45M | $45M | $45M | $44M | $44M | · | $42M | $41M | $40M | $40M | $14M | $9M | $5M | |
| AOCI | $-21.4K | $-20.8K | $-21.5K | $-24.1K | $-23.7K | $-23.9K | $-24.5K | $-23.3K | $-23.3K | $-23.5K | $-23.1K | $-24.1K | $-22.6K | $-23.0K | $-17.7K | $-15.2K | |
| Stockholders' Equity | $28M | $33M | $38M | $35M | $44M | $52M | $40M | $43M | $48M | $28M | $31M | $37M | $43M | $73M | $77M | $81M | |
| Liabilities + Equity | $37M | $47M | $56M | $56M | $45M | $55M | $44M | $55M | $70M | $60M | $71M | $79M | $80M | $73M | $78M | $82M | |
| Shares Outstanding | 10,735,649 | 10,735,649 | 10,735,649 | · | 6,795,779 | 6,795,779 | 6,904,894 | 7,034,259 | 7,717,278 | 8,037,624 | 8,521,159 | 8,699,992 | 8,778,101 | 16,793,980 | 18,209,018 | 19,526,944 |
Nakit Akışı
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | · | $0 | $771.5K | $60.5K | $60.5K | $0 | $-341.8K | $119.2K | $222.7K | $0 | $674.7K | $0 | $0 | $0 | $667 | $3.9K | |
| Operating Cash Flow | $-780.9K | $-1M | $-786.8K | $-979.5K | $-2M | $-1M | $-509.9K | $-1M | $-373.3K | $-333.0K | $-177.1K | $-2M | $343.0K | $-288.4K | $-541.7K | $-2M | |
| Investing Cash Flow | · | $0 | $5M | $-3M | $0 | $0 | $0 | $0 | $-7M | $0 | $-5M | $0 | $0 | $0 | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | $-880 | |
| Stock Repurchased | · | $0 | $401.6K | $0 | $0 | $171.5K | $225.0K | $1M | $742.2K | $1M | $404.7K | $165.0K | $26M | $4M | $4M | $3M | |
| Net Stock Activity | · | · | · | · | $0 | · | · | · | $-742.2K | · | $-404.7K | $-165.0K | $-26M | · | · | · | |
| Financing Cash Flow | $-83.4K | $-169.8K | $543.8K | $6M | $0 | $-171.5K | $-4M | $-11M | $-10M | $-11M | $-7M | $748.7K | $6M | $-4M | $-4M | $-3M | |
| Net Change in Cash | $-864.9K | $-2M | $5M | $2M | $-2M | $-1M | $-4M | $-12M | $-18M | $-11M | $-12M | $-1M | $7M | $-5M | $-4M | $-5M | |
| Taxes Paid | · | · | · | · | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $1.6K | $0 | $0 | $0 |
Kârlılık
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.4% | · | 1.5% | -13.4% | -14.5% | · | -5.3% | -2.2% | 31.2% | · | -0.83% | 3.5% | -3.8% | · | -0.90% | -2.1% | |
| ROE | -14.3% | · | 1.9% | -18.9% | -18.3% | · | -8.5% | -3.7% | 51.8% | · | -1.1% | 4.7% | -4.9% | · | -0.91% | -2.2% |
Likidite ve Solventlik
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 40.3 | · | 12.3 | 14.6 | 18.0 | · | 14.2 | 4.5 | 4.4 | · | 8.2 | 14.1 | 49.2 | · | 88.0 | 58.9 | |
| Quick Ratio | 23.2 | · | 12.2 | 9.9 | 12.7 | · | 14.0 | 4.4 | 4.4 | · | 8.1 | 14.0 | 49.2 | · | 87.7 | 58.7 |
Verimlilik
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.56 | · | $3.55 | · | $6.41 | · | $5.83 | $6.18 | $6.18 | · | $3.68 | $4.23 | $4.87 | · | $4.24 | $4.15 | |
| Revenue / Share | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | |
| Cash Flow / Share | $-0.07 | · | · | · | $-0.29 | · | · | · | $-0.05 | · | · | · | $0.03 | · | · | · | |
| Cash / Share | $1.65 | · | $1.88 | · | $1.94 | · | $2.37 | $2.96 | $4.23 | · | $7.18 | $8.44 | $8.51 | · | $3.99 | $3.94 | |
| EPS (TTM) | $-2.08 | · | $-0.52 | $-0.79 | $0.06 | · | $0.72 | $0.51 | $0.64 | · | $-1.47 | $-0.86 | $-0.69 | · | $0.27 | $0.27 |
Değerleme (TTM)
| Metrik | Eğilim | Q1 2027 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | |
| Net Income TTM | $-16M | · | $-3M | $-7M | $-1M | · | $20M | $23M | $27M | · | $-1M | $-1M | $-6M | · | $-6M | $-6M | |
| Market Cap | $6M | · | $9M | · | $7M | · | $11M | $13M | $15M | · | $19M | $18M | $23M | · | $53M | $57M | |
| P/E | -0.3 | · | -1.6 | -1.2 | 17.0 | · | 2.2 | 3.5 | 3.1 | · | -1.5 | -2.5 | -3.9 | · | 10.7 | 10.9 | |
| P/B | 0.2 | · | 0.2 | · | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.6 | 0.5 | 0.5 | · | 0.7 | 0.7 | |
| P / Tangible Book | 0.2 | · | 0.2 | · | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.7 | 0.6 | 0.6 | · | 0.7 | 0.7 | |
| P / Cash Flow | -7.9 | · | · | · | -3.5 | · | · | · | -40.5 | · | · | · | 68.1 | · | · | · | |
| Earnings Yield | -361.1% | · | -64.2% | -85.0% | 5.9% | · | 44.9% | 28.2% | 32.6% | · | -67.1% | -40.6% | -25.9% | · | 9.3% | 9.2% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Gelir | $0 | $0 | $0 | $0 | $0 |
| Net Gelir | $-19M | $31M | $333.8K | $-4M | $-4M |
| Seyreltilmiş Hisse Başı Kâr | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 |
| Metrik | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Cari Oran | 45.3 | 7.7 | 6.8 | 116.2 | 121.4 |
| Cari Oran | 22.8 | 5.3 | 6.8 | 116.0 | 121.2 |
Bu beyan için veri yok
Bu beyanı oluşturmak için henüz yeterli temel verisi yok.
Kurumsal Sahipler (13F) 37 dosya · $696K toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
37
Tutulan Değer
$696K
Yeni pozisyonlar
3
Çıkan pozisyonlar
5
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 3 (-8 önceki Ç'ye göre) | 5 (+1 önceki Ç'ye göre) | 6 (0 önceki Ç'ye göre) | 11 (+3 önceki Ç'ye göre) | -279K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $218.203 | 283.381 | 31,36% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $95.681 | 124.247 | 13,75% | Hisse senetleri |
| CITADEL ADVISORS LLC | $66.297 | 86.100 | 9,53% | Alım opsiyonu |
| VANGUARD GROUP INC | $54.241 | 74.919 | 7,80% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $43.719 | 56.778 | 6,28% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $34.536 | 44.853 | 4,96% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $29.250 | 37.987 | 4,20% | Hisse senetleri |
| XTX Topco Ltd | $26.319 | 34.180 | 3,78% | Hisse senetleri |
| NORTHERN TRUST CORP | $25.120 | 32.624 | 3,61% | Hisse senetleri |
| JANE STREET GROUP, LLC | $23.149 | 30.064 | 3,33% | Hisse senetleri |
| Schonfeld Strategic Advisors LLC | $20.733 | 26.926 | 2,98% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $18.058 | 23.452 | 2,60% | Hisse senetleri |
| EQUITEC PROPRIETARY MARKETS, LLC | $17.115 | 22.227 | 2,46% | Hisse senetleri |
| COMMONWEALTH EQUITY SERVICES, LLC | $15.600 | 20.255 | 2,24% | Hisse senetleri |
| Tower Research Capital LLC (TRC) | $3.764 | 4.888 | 0,54% | Hisse senetleri |
| UBS Group AG | $3.189 | 4.142 | 0,46% | Hisse senetleri |
| GROUP ONE TRADING LLC | $385 | 500 | 0,06% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $232 | 303 | 0,03% | Hisse senetleri |
| BARCLAYS PLC | $148 | 192 | 0,02% | Hisse senetleri |
| Sachetta, LLC | $11 | 14 | 0,00% | Hisse senetleri |
| HRT FINANCIAL LP | $11 | 15.451 | 0,00% | Hisse senetleri |
| SBI Securities Co., Ltd. | $5 | 6 | 0,00% | Hisse senetleri |
| BFSG, LLC | $4 | 5 | 0,00% | Hisse senetleri |
| CoreCap Advisors, LLC | $3 | 4 | 0,00% | Hisse senetleri |
| CALDWELL SUTTER CAPITAL, INC. | $2 | 2 | 0,00% | Hisse senetleri |
| HARBOUR INVESTMENTS, INC. | $2 | 3 | 0,00% | Hisse senetleri |
| MORGAN STANLEY | $2 | 2 | 0,00% | Hisse senetleri |
| FINANCIAL CONSULATE, INC | $2 | 2 | 0,00% | Hisse senetleri |
| NewEdge Advisors, LLC | $2 | 2 | 0,00% | Hisse senetleri |
| MCF Advisors LLC | $1 | 1 | 0,00% | Hisse senetleri |
| Johnson Financial Group, Inc. | $1 | 1 | 0,00% | Hisse senetleri |
| BlackRock, Inc. | $1 | 1 | 0,00% | Hisse senetleri |
| Abound Wealth Management | $1 | 1 | 0,00% | Hisse senetleri |
| Accredited Wealth Management, LLC | $1 | 50 | 0,00% | Hisse senetleri |
| CWM, LLC | $1 | 1 | 0,00% | Hisse senetleri |
| Covestor Ltd | $0 | 275 | 0,00% | Hisse senetleri |
| HUNTINGTON NATIONAL BANK | $0 | 1 | 0,00% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. ×2 başvurular | 18 Kasım 2025 | 74,00% | Değişiklik | · | SEC |
| Iroquois Master Fund Ltd., Iroquois Capital Management, LLC, Iroquois Capital Investment Group LLC, Richard Abbe, Kimberly Page ×6 başvurular | 16 Haziran 2023 | · | İlk başvuru | · | SEC |
| Nima Montazeri (1) 2 (a) (b), Silver Rock Associates, Inc. (1) 2 (a) (b), Brown Stone Capital, LP (1) 2 (a) (b) ×2 başvurular | 29 Temmuz 2020 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 8 içeriden öğrenenler · 2 yöneticiler · 8 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Joshua Silverman | CEO and President | 07 Ocak 2026 P | 416.250 | 3 | 0 | $80.300 |
| Carlos Trujillo | Chief Financial Officer | 20 Kasım 2023 A | · | 0 | 0 | $0 |
| Michael M Abecassis | Yönetim kurulu üyesi | 31 Mart 2026 J | 22.292 | 0 | 0 | $0 |
| Jonathan Schechter | Yönetim kurulu üyesi | 31 Mart 2026 J | 192.500 | 3 | 0 | $48.200 |
| Wayne Remell Walker | Yönetim kurulu üyesi | 31 Mart 2026 J | 20.625 | 0 | 0 | $0 |
| Robert Weinstein | Yönetim kurulu üyesi | 31 Mart 2026 J | 41.250 | 0 | 0 | $0 |
| Farb Daniel Stuart | Yönetim kurulu üyesi | 28 Aralık 2022 A | · | 0 | 0 | $0 |
| Daniel Allen | Yönetim kurulu üyesi | 28 Aralık 2022 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 1 ETF tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | 0,00% | 56.778 SH | 19 Ağustos 2026 | Günlük |
PMCB Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 6 analist
SAT
0 0,0%
Güçlü Al
0 0,0%
Al
3 50,0%
Tut
1 16,7%
Sat
2 33,3%
Güçlü Sat
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Eyl 14, 2026